UK biotech financing shows early signs of recovery in Q1 2026, led by renewed venture capital activity

London, 27 April 2026 – UK biotech financing showed signs of recovery in the first quarter of 2026, driven by a rebound in venture capital investment and a broader distribution of funding across companies and stages, according to new figures from the BioIndustry Association (BIA).

A growth in investor confidence

Total equity financing reached £552 million between January and March 2026, up from £466 million in Q4 2025, marking a stronger start to the year for the UK’s biotech sector. Venture capital was the primary driver, rising 17% quarter‑on‑quarter to £516 million from £442 million, signalling growing investor confidence following a prolonged period of caution.

While headline totals remain below the £924 million recorded in Q1 2025, last year’s figures were skewed by a small number of mega‑rounds. By contrast, Q1 2026 was characterised by a broader spread of investment, with capital deployed across more companies and stages. Deal activity increased significantly to 25 VC transactions, up 67% year‑on‑year, pointing to a healthier, more active funding environment even as average deal sizes remained more moderate. Moreover, the UK secured 57% of all European biotech venture capital this quarter – an indicator of the ongoing strength of the UK market.

The data highlights a shift away from reliance on a handful of outlier financings and towards a more balanced funding landscape. Later‑stage rounds continued to attract the largest share of capital, while early‑stage activity strengthened in volume terms, reinforcing the depth of the UK’s innovation pipeline.

Public markets remain dormant

However, this recovery has yet to reach public markets. Follow‑on financings increased slightly to £36 million, up from £24 million in Q4 2025, and there were no UK biotech IPOs in Q1 2026, extending a period of inactivity that has persisted since 2022. This underscores the ongoing challenges facing listed biotech companies and the continued importance of private capital and alternative routes to liquidity.

M&A activity enlivens the sector

Despite these headwinds, M&A activity was a standout feature of the quarter. High‑profile acquisitions, including Centessa Pharmaceuticals’ £4.6 billion purchase by Eli Lilly and Amgen’s acquisition of Dark Blue Therapeutics for £626 million, reinforce UK-originated assets as must-haves for international pipelines. Even while the public market window remains narrow, the strategic value of UK companies is being validated at the highest levels.

Jane Wall, Managing Director of BIA, said:

“It comes as great relief to see those green shoots that started showing end of 2025 grow into a more sustained and healthier shift in market dynamics in the first quarter of 2026. While headline figures often fluctuate based on the presence of a few megadeals, the underlying story of Q1 is one of accelerating momentum and a broader distribution of capital across the UK’s innovative ecosystem.

“As we move further into 2026, the architecture for growth is building with strong political support. With deal flow broadening and international interest in our world-class ecosystem high, now is the time to ensure that domestic capital follows the lead of our global peers to fully unlock the value of UK innovation and that the Government delivers its broader commitments through the Life Sciences Sector Plan.”